Předmět: |
|
Zdroj: |
Diabetes Week; 7/8/2024, p189-189, 1p |
Abstrakt: |
New research from Ningxia Medical University in China explores the impact of Nesfatin-1 on type 2 diabetic erectile dysfunction (T2DMED) and its underlying mechanism in regulating the phenotypic switching of corpus cavernosum smooth muscle cells (CCSMCs). The study found that Nesfatin-1 effectively improved body weight, blood glucose levels, and erectile function in diabetic mice. It also regulated the phenotypic switching of CCSMCs by activating the PI3K/AKT/mTOR signaling pathway. These findings suggest that Nesfatin-1 may be a potential treatment for diabetic erectile dysfunction. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|